{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:29:04Z","timestamp":1775017744092,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008635","name":"University of Texas Health Science Center at San Antonio","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008635","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP170345"],"award-info":[{"award-number":["RP170345"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.clgc.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T11:52:02Z","timestamp":1641469922000},"page":"219-226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["RNA sequencing in a penile cancer cohort: an investigation of biomarkers of cisplatin resistance and potential therapeutic drug targets"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-7883","authenticated-orcid":false,"given":"Christine","family":"Ibilibor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6893-1926","authenticated-orcid":false,"given":"Amanda L.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanzhang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sitai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Alonzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-1435","authenticated-orcid":false,"given":"Ronald","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.01.002_bib0001","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.clgc.2022.01.002_bib0002","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1002\/ijc.29670","article-title":"Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration","volume":"137","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2022.01.002_bib0003","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU guidelines on penile cancer: 2014 update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.01.002_bib0004","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5173\/ceju.2014.02.art2","article-title":"Metastatic penile carcinoma - an update on the current diagnosis and treatment options","volume":"67","author":"Barski","year":"2014","journal-title":"Cent European J Urol"},{"issue":"10 Suppl","key":"10.1016\/j.clgc.2022.01.002_bib0005","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.23743","article-title":"Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003","volume":"113","author":"Hernandez","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2022.01.002_bib0006","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bju.12993","article-title":"Steering Committee of the Swedish National Penile Cancer R. Swedish National Penile Cancer Register: incidence, tumour characteristics, management and survival","volume":"117","author":"Kirrander","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.01.002_bib0007","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ijc.25355","article-title":"Incidence trends and survival of penile squamous cell carcinoma in the Netherlands","volume":"128","author":"Graafland","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clgc.2022.01.002_bib0008","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.juro.2006.11.038","article-title":"Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma","volume":"177","author":"Bermejo","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.01.002_bib0009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clgc.2014.06.005","article-title":"Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer","volume":"13","author":"Djajadiningrat","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2022.01.002_bib0010","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bju.13054","article-title":"Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma","volume":"117","author":"Houede","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.01.002_bib0011","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2007.02.006","article-title":"Neoadjuvant chemotherapy in advanced penile carcinoma","volume":"52","author":"Leijte","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.01.002_bib0012","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eursup.2017.07.003","article-title":"Systemic Therapy for Penile Cancer[Figure presented]","volume":"17","author":"Necchi","year":"2018","journal-title":"European Urology, Supplements."},{"key":"10.1016\/j.clgc.2022.01.002_bib0013","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.euf.2017.02.009","article-title":"E2F1 Signaling is Predictive of Chemoresistance and Lymphogenic Metastasis in Penile Cancer: A Pilot Functional Study Reveals New Prognostic Biomarkers","volume":"4","author":"Fenner","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2022.01.002_bib0014","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2559.2011.04062.x","article-title":"DNA repair gene excision repair cross complementing-group 1 (ERCC1) in head and neck squamous cell carcinoma: analysis of methylation and polymorphism (G19007A), protein expression and association with epidemiological and clinicopathological factors","volume":"60","author":"Lima","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.clgc.2022.01.002_bib0015","first-page":"2286","article-title":"Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer","volume":"8","author":"Lord","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2022.01.002_bib0016","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.01.002_bib0017","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1159\/000343636","article-title":"RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin","volume":"35","author":"Park","year":"2012","journal-title":"Onkologie"},{"key":"10.1016\/j.clgc.2022.01.002_bib0018","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2407-12-187","article-title":"ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy","volume":"12","author":"Sun","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2022.01.002_bib0019","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.clgc.2016.01.013","article-title":"Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer","volume":"14","author":"Dorff","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2022.01.002_bib0020","article-title":"Robustness of RNA sequencing on older formalin-fixed paraffin-embedded tissue from high-grade ovarian serous adenocarcinomas","volume":"14","author":"Zhao","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clgc.2022.01.002_bib0021","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3390\/cells10040814","article-title":"Penile Cancer-Derived Cells Molecularly Characterized as Models to Guide Targeted Therapies","volume":"10","author":"Kuasne","year":"2021","journal-title":"Cells."},{"key":"10.1016\/j.clgc.2022.01.002_bib0022","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jmcb\/mjt035","article-title":"E2F1 promotes angiogenesis through the VEGF-C\/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B","volume":"5","author":"Engelmann","year":"2013","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.clgc.2022.01.002_bib0023","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s10585-013-9581-x","article-title":"Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis","volume":"30","author":"Matsumoto","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.clgc.2022.01.002_bib0024","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1159\/000490022","article-title":"Efficacy of the MEK Inhibitor Cobimetinib and its Potential Application to Colorectal Cancer Cells","volume":"47","author":"Gong","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.clgc.2022.01.002_bib0025","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.1200\/JCO.2004.08.054","article-title":"Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196","volume":"22","author":"Sparano","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:34:15Z","timestamp":1761564855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322000027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1558767322000027"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.01.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA sequencing in a penile cancer cohort: an investigation of biomarkers of cisplatin resistance and potential therapeutic drug targets","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}